measurable levels in blood: generally, levels that can be measured with adequate sensitivity and specificity are achieved only around 6 h after the onset of cardiac necrosis. Recently, however, a high-sensitivity troponin T (hsTnT) assay has been developed, permitting measurement of concentrations that are 10-fold lower than those measurable with conventional assays. 13, 14 A second problem remains, however; namely, troponin levels are also reported to be elevated in patients with other medical conditions, such as congestive heart failure, myocarditis, or renal failure, making the test less suitable for diagnosis of ACS. [15] [16] [17] In the present study we compared the efficacy of using troponin levels, measured with the hsTnT assay, to other cardiac biomarkers, in patients with chest pain.
Methods

Patient Selection
This was a multicenter, cross-observational study, in which 543 patients with chest pain (lasting >20 min within 24 h of admission) were enrolled. These patients had all visited the emergency department of hospitals by ambulance during the 3-year recruitment period from March 2006 to April 2009. Of these, the following patients were excluded: those (1) who were unwilling or unable to provide informed consent; (2) who were admitted with an identified chronic kidney disease, as indicated by serum creatinine level >1.5 mg/dl on presentation; or (3) who were diagnosed with and treated for malignant disease or collagen disease; or (4) whose CRP levels were >10 mg/dl, with an identified non-cardiac cause of chest pain on presentation. 18, 19 Finally, a total of 432 subjects were analyzed (Figure 1 ).
Informed consent was obtained from all subjects. The study was approved by the ethics committees of Juntendo University Shizuoka Hospital and Juntendo University Nerima Hospital as well as Itabashi Chuo Hospital, and was conducted in accordance with the Helsinki Declaration of 1971, as revised in 1983.
Clinical Assessment
All patients underwent an initial clinical assessment that included a clinical history, physical examination, 12-lead electrocardiogram (ECG), continuous ECG monitoring, pulse oximetry, standard blood pressure measurements, and chest radiography in the emergency department.
Weight, height, body mass index, ECG, and systolic and diastolic blood pressures (measured in the supine position) were assessed under standardized conditions. Information with respect to smoking status (current or former smoker vs. non-smoker) was obtained via a questionnaire.
Final Diagnosis
Diagnostic outcome was categorized into 4 groups: (1) STelevation myocardial infarction (STEMI); (2) non-STEMI (NSTEMI); (3) unstable angina (UA); and (4) no ACS (which included cases of atypical chest pain). Diagnoses were adjudicated by 2 senior cardiologists according to the Joint Guidelines of the European Society of Cardiology and American College of Cardiology Committee. 20 The diagnosis of atypical chest pain was based on absence of significant findings indicative of cardiovascular problems, including laboratory tests, ECG, and chest radiography. Such a diagnosis was subsequently confirmed when follow-up by chart review by a senior cardiologist indicated that the patient did not return to a hospital 
Laboratory Analysis
Venous blood samples were drawn in the emergency department on admission and were stored at -70°C, for <3 years, until analysis. All measurements were performed in duplicate and blinded to patient data.
Serum troponin was measured on hsTnT assay using an Elecsys 2010 system (Roche Diagnostics, Basel, Switzerland). Serum H-FABP measurement was performed using the MARKIT-M H-FABP assay (DS Pharma Biomedical, Osaka, Japan). Serum hsCRP assay was carried out with latex-enhanced immunonephelometry reagents (SRL, Tachikawa, Tokyo, Japan) on a BN ProSpec analyzer (Siemens Healthcare Diagnostics, Deerfield, IL, USA). Plasma MPO or PTX3 was determined on sandwich immunoassay (Mercodia, Uppsala, Kingdom of Sweden, or Perseus Proteomic, Tokyo, Japan).
Cut-offs for hsTnT, H-FABP, and hsCRP were defined according to the manufacturers of the respective assay kits as follows: hsTnT, 0.014 ng/ml; H-FABP, 6.2 ng/ml; and hsCRP, 1.5 ng/ml. 21 Cut-off concentrations for PTX3 (3.48 ng/ml) and MPO (87.6 μg/ml) were determined according to the highest sensitivity and specificity criterion derived directly from the receiver operating characteristic (ROC) curves.
Statistical Analysis
Continuous variables are presented as medians (with interquartile range), and categorical variables are presented as numbers and percentages. Continuous variables were compared using Mann -Whitney U-test and categorical variables with the Pearson chi-squared test. Parametric tests such as Pearson's product-moment correlation coefficient analysis were used after log transformation of original data, because biomarker values were not normally distributed, but approximated a log-normal distribution. Pearson's product-moment correlation coefficient (R) was used to study the relationship between the biomarkers.
The ROC curves were constructed to assess the sensitivity and specificity of cardiac biomarker measurements obtained at specific time points and to compare their ability to diagnose ACS. The comparison of areas under the ROC curves (AUC) was performed. The AUC are expressed with confidence intervals (CI).
All hypothesis testing was 2-tailed, and P<0.05 was considered statistically significant. Statistical analysis was performed using SPSS version 16.0 (SPSS, Chicago, IL, USA).
Results
Patient Characteristics
Baseline characteristics of the 432 subjects are given in Table 1 . There were no significant differences in patients with ACS or without ACS, besides the presence of diabetes mellitus or current smoking. ACS was the final diagnosis in 69.0% of the patients (STEMI in 52%, NSTEMI in 9.0%, and UA in 8.8%; Figure 1 ). The non-ACS group included patients with vasospastic angina pectoris (VAP, 4.9% of the total cohort), patients with cardiac symptoms from causes other than coronary artery disease (7.1%; of which patients with Takotsubo myocarditis accounted for 3.4%), and patients with symptoms of unknown origin (19.0%).
Cardiac Biomarkers
The relation between cardiac biomarkers was investigated using Pearson's correlation coefficient ( Table 2) . A highly sta- Receiver operating characteristic curves showing diagnostic performance of the 5 cardiac biomarker assays on blood samples of the overall cohort, obtained at presentation for the diagnosis of acute coronary syndrome. H-FABP, heart fatty acid-binding protein; hsCRP, high-sensitivity C-reactive protein; hsTnT, high-sensitivity troponin T; MPO, myeloperoxidase; PTX3, pentraxin 3.
tistically significant positive correlation was observed in patients with chest pain between log hsTnT and both log H-FABP and log PTX3. Pearson's correlation coefficient (R) and the corresponding P-values for these correlations were R=0.69 and 0.60, respectively, and P<0.001.
Diagnostic Accuracy of Cardiac Biomarkers at Presentation
The diagnostic accuracy for ACS, as quantified using AUC, is shown in Figure 2 . Table 3 ). Although both sensitivity and specificity of the new vascular inflammation biomarker, PTX3, was superior to those of the classical inflammation biomarker, hsCRP, its specificity was still low. The pathophysiology underlying development of STEMI vs. NSTEMI would be expected to be different, and the release-kinetics of biomarkers would therefore also be different. Therefore, we further analyzed patients with STEMI and NSTEMI, separately (Tables 4), but we found that diagnostic performance tended to be similar. The sensitivity (89.7% and 82.7% in STEMI and NSTEMI, respectively), negative LH (0.2, 0.3), and negative predictive value (78.1%, 86.3%) were the highest for hsTnT, but H-FABP had the highest specificity (78.2%, 78.2%), positive LH (3.9, 2.7), and positive predictive value (86.8%, 60.3%) in patients with STEMI, as well as in those with NSTEMI.
Overall, the values obtained for specificity were not particularly high in the present study. Therefore, we investigated the characteristics of the non-ACS groups who had levels higher than the cut-off for each biomarker (ie, false-positive results). All biomarkers, except for H-FABP, tested positive in approximately 20% of subjects with atypical chest pain; H-FABP tested positive in only approximately half of these patients (11%). Takotsubo cardiomyopathy patients frequently tested positive for all biomarkers, while VAP caused increased levels of hsTnT in 62% of patients, presumably because of minor myocardial injury caused by this condition (Table S1) .
Cardiac Biomarkers at Presentation in Patients With Recent Onset of Chest Pain
Next, we investigated serial diagnostic measurements taken for each cardiac biomarker after the onset of chest pain. Although the sensitivity of hsTnT was the highest in patients who presented 3 h after the onset of chest pain, this marker performed worst in terms of specificity throughout the time course (Figure 3a) . Positive LH and predictive value of H-FABP were superior to all biomarkers in patients who presented >3 h after the onset of chest pain (Figures 3b,c) . In contrast, the specificity of hsCRP was the highest in patients who presented within 6 h after chest pain, and a positive LH for this marker was the highest in patients who presented within 2 h. Although the sensitivity was worst (Figure 3d; Table 5 ), the negative LH was >0.6 through the time course and the AUC was not low except <2 h after onset of chest pain. The AUC of hsTnT, H-FABP, and PTX3 gradually increased in a time-dependent manner. Four hours after the onset of chest pain, the AUC of hsTnT and H-FABP was >0.70, but throughout all time points, H-FABP was superior to hsTnT. Interestingly, among patients who presented within 2 h after the onset of chest pain (n=85), the AUC for MPO was the highest among the cardiac biomarkers tested (AUC =0.82; 95%CI: 0.69-0.94), and the AUC was >0.70 at all points. When using a combined measurement of H-FABP and MPO, sensitivity was 69.2%, and the specificity was 84.2%, while positive LH was 4.4, and negative LH was 0.4. Thus, the combination of H-FABP and MPO assay results may improve the diagnostic performance of biomarker testing for patients who present within 2 h after the onset of chest pain.
Discussion
This multicenter study examined the diagnostic performance of a new, sensitive cardiac troponin assay, in comparison with tests for other biomarkers, for the early diagnosis of ACS at the time of presentation to the emergency department. Although hsTnT is much improved over the conventional troponin T assay system, the present results show that many more falsepositive hsTnT tests than false-positive H-FABP tests occurred in patients with non-ACS. The present study contained patients with VAP (4.7%) and Takotsubo myocarditis (3.6%). Thus, cardiac myocardial injury caused by these diseases can generate false-positive findings in assays, when considering positive tests in the presence of chest pain as indicative of ACS (Table S1 ). This may lead to a reduction in diagnostic performance, especially in the specificity of the hsTnT assay. Patients with Takotsubo cardiomyopathy and VAP typically complain of chest pain and have inverted T or ST elevation; coronary angiography is therefore required to confirm diagnosis, or at least to rule out ACS in these cases. Thus, physicians must consider that these cases may be included when finding elevated cardiac biomarkers in patients with chest pain.
As expected, however, the availability of the hsTnT assay has much improved the sensitivity of troponin T testing; its sensitivity was superior to all biomarkers throughout the time course in the present study. The hsTnT assay may be particularly useful to rule out ACS because the negative LH of a positive hsTnT test was 0.2 in the present study. In contrast, a positive LH of H-FABP was 3.6, the highest among the cardiac biomarkers evaluated in the present study, potentially making it a more accurate test for ACS. The AUC of both hsTnT and H-FABP assays were >0.80 in all subjects.
Despite this, it is still difficult to determine diagnosis in patients with ACS who present at emergency centers with chest pain within 2 h after onset of the pain. Interestingly the AUC of MPO was the highest (0.82; 95%CI: 0.69-0.94) among all biomarkers tested in this cohort. The principal sources of MPO are activated neutrophils and monocytes. MPO has been identified in human plaques; 22 after activation, MPO was released quickly from neutrophils, and levels became elevated in patients with ACS. In contrast, H-FABP is known to increase faster in patients with early onset ACS. 23 Thus, the combination of H-FABP and MPO assays may improve the diagnostic performance of cardiac biomarker testing. Moreover, it seems to be sensible to consider that ACS is present in those patients who presented within 2 h after the onset of chest pain if both H-FABP and MPO tested positive. A limitation of the present study was the low prevalence of NSTEMI and UA compared to that of STEMI (9% and 8.8% vs. 52%). The present data were collected from 3 hospitals. Two of these hospitals are recognized as advanced emergency medical service centers; therefore, paramedic emergency medical technicians might transport patients with STEMI to these hospitals when their ECG clearly show elevation of the STsegment, accounting for the increased numbers of patients with STEMI. As seen in Table 4 , however, hsTnT was the most sensitive biomarker, and H-FABP the most specific one, in patients with NSTEMI or STEMI; thus, the ratio of STEMI to NSTEMI patients is not likely to have influenced the results. Moreover, the present NSTEMI patient data correspond to those of a previous report. 24 In conclusion, the hsTnT assay is an excellent diagnostic test that can be performed to rule out ACS in patients with chest pain but, due to its high sensitivity, it is prone to falsepositive testing. Overall, the diagnostic performance of the hsTnT biomarker is similar to that of H-FABP. Moreover, in cases in which patients present at the emergency department soon after the onset of chest pain, the combined use of MPO and H-FABP is optimal for improving the early diagnosis of ACS. Abbreviations see in Table 3 .
